Baptist Health Institutional Review Board. Study Closure Report (Expedited Review) IRB #: Study Title:

Similar documents
I. Summary. II. Responsibilities

UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD CONTINUING REVIEW AND REAPPROVAL OF RESEARCH

UNIVERSITY OF GEORGIA Institutional Review Board

CONTINUING REVIEW 3/7/2016

UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER INSTITUTIONAL REVIEW BOARD CONTINUING REVIEW OF RESEARCH

University of Pennsylvania Institutional Review Board. Reliance Agreement Guidance: Post-Approval Submissions

Children s Hospital of Philadelphia Committees for the Protection of Human Subjects Policies and Procedures Continuing Review of Approved Research

CUNY HRPP Procedures: Multisite Non-Exempt Human Subjects Research

University of Pennsylvania Institutional Review Board. Reliance Agreement Guidance: Penn as Central IRB FAQ

Reporting an Unanticipated Problem Involving Risks to Subjects or Others (UPIRTSO) to the IRB

The Children s Hospital of Philadelphia Committee for the Protection of Human Subjects Policies and Procedures. Cooperative Agreements

Human Research Protection Program Policy

Signature Date Date First Effective: Signature Date Revision Date:

SOP #2-2 Version #1 Date First Effective: December 14, Page 1 of 6

Yale University Human Research Protection Program

Submitting Continuing Reviews and/or Amendments to the IRB

SUSPENSION OR TERMINATION OF HUMAN SUBJECTS RESEARCH

I. Summary. II. Responsibilities

Independent Ethics Committees

To assure knowledge and compliance by documenting the continuing review procedure of approved projects for the IRB.

Standard Operating Policy and Procedures (SOPP) 3:

Tuesday, May 15, Please be sure to sign in and take copies of each handout.

AMENDMENTS TO PREVIOUSLY APPROVED RESEARCH 3/01/2016

CONTINUING REVIEW OF APPROVED IRB PROTOCOLS

SOP 801: Investigator Qualifications and Responsibilities

UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD PROCEDURES FOR FULL BOARD REVIEW

Screening and Enrollment Log. List of all subjects screened and all subjects screened and enrolled in the study.

External IRB Instructions for the Registration Pathway in OSIRIS

Florida State University IRB Standard Operational Procedures

OHRP Guidance on Written IRB Procedures

Michigan State University Human Research Protection Program

Lapse in IRB Approval

7.0 DEVIATION and EXCEPTION of a PREVIOUSLY APPROVED PROTOCOL

HEALTH CARE SYSTEMS RESEARCH NETWORK

SOP 407: PROTOCOL DEVIATIONS AND UNANTICIPATED PROBLEMS

University of Pennsylvania Institutional Review Board. Reliance Agreement Guidance: How to Apply for External IRB Review

Supersedes Document Dated: 7/7/11. SOP: RR 401 Version No.: 07 Version Date: 9/8/15 EXPEDITED REVIEW 1. POLICY

Issue in IRB Approvals:

IRB-REQUIRED INVESTIGATOR ACTIONS

NONCOMPLIANCE. 1. Overview

PRINCIPAL INVESTIGATOR S ACKNOWLEDGMENT OF RESPONSIBILITIES

University of Iowa External/Central IRB Reliance Process Standard Operating Procedure (SOP)

Section 8. Continuing Review of Ongoing IRB-Approved Research (Revised 7/1/10)

Human Subjects in Research Review and Monitoring Form. Not applicable

Study Management SM STANDARD OPERATING PROCEDURE FOR Interactions with the Institutional Review Board (IRB)

RESEARCH PROTECTIONS OFFICE

CONTINUING REVIEW CRITERIA FOR RENEWAL

Signature Date Date First Effective: Signature Date Revision Date: 07/18/2011

Yale University Institutional Review Boards

Effective Date: January 16, 2012 Policy Number: MHC_RP0107. Revised Date: November 2, 2015 Oversight Level: Corporate

Ceded IRB Review. The project involves prisoners or other vulnerable populations that require special considerations.

RESEARCH SUBMISSION REQUIREMENTS

EXPEDITED REVIEW. Terms used in this policy, but not defined herein shall have the meanings set forth in the Glossary.

DOCUMENTATION OF IRB DISCUSSIONS AND DECISIONS ( IRB MINUTES)

COMPLIANCE MONITORING

Investigator Manual Version date: April 1, 2010

Effective Date Revisions Date Review by the Convened Institutional Review Board

CONTINUING REVIEW CRITERIA FOR RENEWAL

Administrative Hold, Suspension, or Termination of IRB Approval

IRB Authorization Agreement Implementation Checklist and Documentation Tool

The IRB reviews and monitors human subjects research conducted by Columbia College Chicago faculty, staff, and students.

Date Effective 4/21/2008 Identification

Procedure Department: HUMAN RESEARCH PROTECTIONS PROGRAM Policy Number: II.B.1

To assure knowledge and compliance by documenting the annual administrative review and continuing IRB review of non-exempt projects for the IRB.

Title: EXPEDITED IRB REVIEW OF HUMAN SUBJECTS RESEARCH

SYRACUSE UNIVERSITY HUMAN RESEARCH PROTECTION PROGRAM STANDARD OPERATING PROCEDURES

Wayne State University Institutional Review Board

SYRACUSE UNIVERSITY HUMAN RESEARCH PROTECTION PROGRAM STANDARD OPERATING PROCEDURES 02 06/30/10 08/01/07 1 OF 6

CUNY HRPP Policy: Suspension or Termination of Human Subject Research

SMART IRB Agreement Implementation Checklist and Documentation Tool

Chapter 4 Institutional Review Board (IRB) Roles and Authorities

Children s Hospital of Philadelphia Committees for the Protection of Human Subjects Policies and Procedures. IRB Review Processes

IRB Chair Responsibilities

Investigator Manual. If you have questions about whether an activity requires IRB review, contact the IRB Office.

Initial Review. Approved By: Michele Kennett, JD, MSN, LLM Associate Vice Chancellor for Research. Table of Contents

Info Sheet - Operations Office for Human Research Studies

IOWA STATE UNIVERSITY Institutional Review Board. Policy on IRB Review of Protocol Deviations and Noncompliance for Non-exempt Research

Institutional Review Board Standard Operating Procedure. Suspension and Termination of IRB Approval

Commercial/ Central IRB An independent organization that provides IRB review services

Ceded IRB Review. The University of Arizona has standing agreements in place for the following entities regarding ceded IRB review:

Human Research Protections Program Medical College of Wisconsin and Froedtert Memorial Lutheran Hospital

POLICY NO EXEMPT RESEARCH... 4 POLICY NO DISCLOSURE OF RESEARCH LAB TEST RESULTS... 5

What s New in GCP? FDA, OHRP Issue Harmonized Guidance on Transferring IRB Oversight of Clinical Studies

Minot State University Institutional Review Board ANNUAL UPDATE/REVISION/PROJECT COMPLETION REPORT

IRB MEETING ADMINISTRATION

SOP Title Review of Research: Devices for Humanitarian Uses

University of Kentucky Office of Research Integrity and Institutional Review Board Standard Operating Procedures SOP #4-1 Revision #6

Arkansas Tech University Institutional Review Board

Your Roadmap to Single IRB Review Serving as a Reviewing IRB

Effective Date: January 16, 2012 Policy Number: Appendix II. Revised Date: November 2, 2015 Oversight Level: Corporate

IRB Minutes Quality Improvement Assessment

Version 1. Submission Guide and Policies

University of Wisconsin Colleges Administrative Policy #56 NON-COMPLIANCE IN HUMAN SUBJECTS RESEARCH

Guidance for IRBs, Clinical Investigators, and Sponsors IRB Continuing Review after Clinical Investigation Approval

DEPARTMENT OF HEALTH & HUMAN S E RVICES, 'mgr,':~~ MAY WARNING LETTE R

INTRA-INSTITUTIONAL COMMUNICATION

Cayuse IRB Policy and Procedure Manual

A Guide to SMART IRB s Resources for IRB and HRPP Personnel

THE DUHS IRB REVIEW PROCESS 8/13/2014

AUTHORITY AND PURPOSE

Transcription:

Baptist Health Institutional Review Board Study Closure Report (Expedited Review) (Please complete ALL sections of this form. Incomplete forms will be returned) Principal Investigator: E-mail: Phone #: Pager#: Research Coordinator: ((Name, phone #, email) IRB #: Study Title: Date of IRB Expiration: ALL QUESTIONS MUST BE ANSWERED. 1. We wish to close this study: All interventions are completed on all subjects and only statistical analysis of already collected data that is now de-identified or no links to identifiers remain. NOTE: You may close the study. If so, you must attach a letter signed by the PI certifying that the data as been de-identified. All interventions, data collection, and data analysis are completed.

2. During this review period, have there been ANY changes, no matter how minor, to any part of this research project, including the IRB approved forms? No. Yes. If yes, select one: All changes implemented to this project have been previously reported to and approved by the IRB. Changes have been implemented but were not submitted to the IRB. Explain: 3. Are you submitting any new revisions along with this Study Closure Report? No. Yes. You must include: An amendment form, all altered pages, both a tracked and untracked copy, and a summary of the changes. 4. Study Sponsor: Is your study sponsored? No. Skip to question 5. Yes. Provide the name of all the study sponsors: 5. Have there been any changes in the potential conflict of interest described in the initial submission for any of the investigators (including Principal Investigator, Co- Investigator, Sub-Investigator, etc.) associated with this project? Describe: Please submit a new Financial Conflict of Interest form for each Investigator participating in this study. Any studies submitted without the Financial Conflict of Interest forms will be returned. 6. External audit: Has the Food and Drug Administration (FDA), study sponsor or other agency audited this project during this review period? If yes, have these reports been submitted? Yes No If no, indicate who conducted the audit and when you expect to submit the reports to the IRB:

7. Have any subjects enrolled in this project? No. Explain why you have not started this project: Yes. # of subjects who have signed an informed consent document. # of subjects enrolled since previous IRB review. # of subjects consented that did not participate since previous IRB review (include an explanation for each). Have you enrolled more subjects than currently listed in the project s last approved protocol? Explain: 8. Provide a description of study activities to date, including any difficulties in recruiting subjects: 9. Was an Informed Consent Form (ICF) signed by each subject or their legally authorized representative? Yes No Explain: Did all subjects or their legally authorized representative receive a copy of the ICF? Yes No Explain: 10. Describe any subject complaints, concerns, or comments about the study: 11. Have all protocol deviations been reported to the IRB? Yes No Please attach a log of all protocol deviations that have occurred since the last IRB approval. 12. Does this study have an oversight committee or Data Safety Monitoring Board (DSMB)? If yes, what was the date of the last report:. Please submit this report with this form. A report is not available. Date report will be available:

13. Is there any other new information (from the research itself or other sources) that alters the risk/benefit ratio of this study? Explain: 14. Risk/Benefit ratio evaluation: Did the Risk/Benefit ratio of this study change for any reason during this review period? Explain: 15. Since the Previous IRB review approval, have any unanticipated problems involving risks to participants and/or serious unanticipated research related adverse events occurred at sites where a BMC/WCH investigator is involved in the conduct of the research or is responsible for regulatory reporting? If yes, Total number of events/problems previously reported to the IRC? Are there any events that have not been reported to the IRB? Explain: 16. Is this a multi-center study? If yes, since the last IRB review approval, have any unanticipated problems involving risk to participants and/or serious or unanticipated and research related events occurred at sites where a BMC/WCH investigator is not involved in the conduct of the research or is not responsible for regulatory reporting (off-site adverse events)? Total number of off-site adverse events previously reported to the IRB. Total number of off-site adverse events not previously reported to the IRB. Please explain why these were not reported.

Print a copy of this form and: Type AND sign your name below. Submit an electronic copy to ircsubmission@bmcjax.com along with a scanned copy of the signature page with original signature. Submit revised Financial Conflict of Interest form. Make a copy of the signed report for your regulatory file. In addition to the above responses, I confirm that a current IRB-approved consent form has been signed, dated, and is retained in my files for every participant enrolled in this study and a copy was provided to the person who signed this form (if use of a consent form was required). I also confirm that no changes to study procedures or the consent form(s) were initiated without prior IRB approval. Person completing Study Closure Form: Signature: Date: Principal Investigator: Signature: Date: NOTE: This form must be signed by the PI unless you have previously notified the IRB of a Transfer of PI responsibility.